Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

According to a survey performed by Vertex Group, a New York-based business process management firm, 52 per cent of Indian ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Over half of employees in India are facing burnout due to poor work-life balance, according to a survey by Vertex Group. The ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Detailed price information for Vertex Resource Group Ltd (VTX-X) from The Globe and Mail including charting and trades.

Vertex (NASDAQ:VERX – Free Report) had its target price trimmed by Jefferies Financial Group from $62.00 to $48.00 in a ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters and the stock price to rise further.” ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...